Discovery
Clinical Pharmacology & Therapeutics (2007) 82, 591–594. doi:10.1038/sj.clpt.6100373; published online 26 September 2007
Endocannabinoid System and Cardiometabolic Risk
L E Saavedra1
1General Cardiology & Coronary Care Unit Services, CCR ASCARDIO, Barquisimeto, Venezuela
Correspondence: LE Saavedra, (leonardosaavedra@intercable.net.ve)
Abstract
The increasing prevalence of overweight and obesity counteracts the favorable advances of risk factor management achieved for cardiovascular disease (CVD) prevention. Obese and overweight individuals are at increased risk for CVDs and diabetes mellitus, a risk pattern called "cardiometabolic risk." There is a growing interest concerning the role of the endocannabinoid system in energy metabolism and how blockade of cannabinoid receptors (CB1) may optimize fat distribution, insulin sensitivity, and blood lipids to improve cardiovascular risk profile.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Impact of Abdominal Adiposity on Cardiovascular Disease Predictors: What Is the Missing Link?American Journal of Hypertension News and Views
